Medicine safety is not nearly as straight-forward as most people would expect. Virtually all medicines have the potential for adverse reactions. In addition, there are often conflicting reports on how frequent adverse reactions occur; furthermore, negative studies demonstrating safety may be published less frequently due to publication bias.
This problem is compounded by the frequent misunderstanding of statistics. Frequently, risks of medications are expressed as an odds ratio. So, if an adverse reaction occurs twice as often with the medication than without the medication, the odds ratio would 2.0. Yet, if the adverse reaction is rare (eg. one in a million), then the absolute increase in risk remains minuscule.
Proton pump inhibitors have received a lot of press, often about rare increases in adverse reactions. But, there are many potential benefits to these medications and numerous studies demonstrating fairly good safety profiles. A few more studies (thanks to Ben Gold for these references) on their safety have recently been published:
- 1. “Long-term Proton Pump Inhibitor Use is Not Associated with Changes in Bone Strength and Structure” LE Targownik et al. Am J Gastroenterol 2017; 112: 95: 101.
- 2. “Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.” DM Faleck et al. Am J Gastroenterol 2016; 111: 1641-8.
In the first study, the authors examined 52 PPI-users (>5 yrs) and 52 non-PPI users with mean age of 65 years. They underwent quantitative CT , DXA, and markers of bone metabolism. “There were no differences detected..between the two groups.” The conclude that PPIs were not associated with changes that increase a risk of fracture and “provide further evidence that the association between PPI use and fracture is not causal.”
In the second study, the authors analyzed data from 14 ICUs 2010-2013 and identified 18,134 patients (mean age 66-67 yrs) who met inclusion criteria. 271 (1.5%) developed Clostridium difficile infection (CDI) in the ICU. The main risk factor for CDI was antibiotics with adjusted Hazard Ratio (aHR) of 2.79. “There was no significant increase in risk for CDI associated with PPIs in those who did not receive antibiotics (aHR 1.56; 95% CI, 0.72-3.35).” “PPIs were actually associated with a decreased risk for CDI in those who received antibiotics (aHR 0.64; 95% CI 0.48-0.83).” The authors also noted that even those who received the highest doses of PPIs, “there was no risk for health-care facility-onset CDI.”
My take: PPIs can be life-saving medications and can alleviate a lot of suffering. These studies pushback on some of the concerns about PPI risk.
Related blog posts:
- More advice on PPIs
- No Effect of Proton Pump Inhibitors and Irritability on Crying …
- PPI Side Effects: “Dissecting the Evidence” | gutsandgrowth
- How Proton Pump Inhibitors Can Cause Infections …
- Do medicines work for GERD infants? | gutsandgrowth
- “Decision Fatigue” & 1000 Posts | gutsandgrowth
- GERD Treatment in Infants: “Friend or Foe” | gutsandgrowth
- Failure of PPI test | gutsandgrowth
- One for the PPI team | gutsandgrowth